近日，钛媒体2025 EDGE AWARDS全球创新评选榜单正式揭晓，以岭药业(002603.SZ)入选年度全球化 公司榜，荣膺「全球化先锋企业」称号。 作为中医药理论创新的代表，以岭药业以络病理论为核心研发支撑，构建了体系化的中药产品矩阵。依 托这一创新理论，公司研发的系列中药产品已成功进入全球50多个国家和地区，覆盖「一带一路」共建 国家及欧美、非洲重点市场。其中，通心络胶囊以「药品」身份纳入越南医保目录，成为当地冠心病治 疗一线用药；八子补肾胶囊完成8国市场准入，借助主流跨境电商平台切入欧美消费市场，实现医疗端 与消费端双场景全球化布局，让中医药理论创新成果转化为全球可及的健康产品。 T | BARA | | - EDGE | NEXT | BARONS 125 I II = AWAR 创新评选 全球化 先锋企业 年度全球化公司榜 以岭药业 ● 为破解中医药出海的认知与标准壁垒，以岭药业以循证医学为关键抓手，为产品国际化筑牢科学根基。 公司累计开展40余项高质量临床研究，核心产品的疗效数据多次登上《美国医学会杂志》《自然・医 学》等国际顶级学术期刊，获得全球医学界广泛认可。其中，芪苈强心胶囊治疗慢性心衰 ...

Core Viewpoint - The 21st century is witnessing a shift in life sciences research from Western to Eastern methodologies, aligning with Traditional Chinese Medicine (TCM) principles of holistic regulation and syndrome differentiation [1] Group 1: Research and Development Achievements - Professor Wu Yiling has developed the "Vascular Theory" through national research projects, leading to significant breakthroughs in the prevention and treatment of vascular diseases [1] - Three patented traditional Chinese medicines, known as "Tongluo Sanbao" (Tongxinluo Capsules, Shensongyangxin Capsules, and Qiliqiangxin Capsules), have been developed under this theory, demonstrating solid scientific evidence and clinical efficacy in treating cardiovascular diseases [1][5] Group 2: Clinical Research Outcomes - Tongxinluo Capsules have shown to stabilize vulnerable plaques and reduce the incidence of vascular events by 36%, with a 30% reduction in cardiovascular mortality risk and a 74% decrease in one-year recurrence risk, as published in JAMA [3] - Shensongyangxin Capsules have been proven to effectively treat ventricular premature beats and atrial fibrillation, outperforming conventional drugs in certain studies, and have shown a 40.4% reduction in atrial fibrillation recurrence risk post-ablation [4] - Qiliqiangxin Capsules have significantly reduced the risk of major composite events in chronic heart failure patients by 22%, with notable reductions in hospitalization and cardiovascular death risks [5] Group 3: Global Recognition and Impact - The success of "Tongluo Sanbao" in international markets has established a positive image for TCM and provided a model for its high-quality development [5][6] - The journey of "Tongluo Sanbao" reflects the integration of ancient wisdom with modern scientific research, showcasing TCM's potential to address global cardiovascular health challenges [6]

Core Viewpoint - The announcement highlights that Beijing Yiling Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shijiazhuang Yiling Pharmaceutical Co., Ltd., has successfully negotiated to include its product Qifang Bitong Pian in the National Medical Insurance Directory for 2025, which is expected to enhance market promotion and sales scale for the company [1][2]. Group 1: Product Inclusion in National Medical Insurance - Qifang Bitong Pian is a proprietary product developed by the company, classified as a Class 1 traditional Chinese medicine, and is used for treating persistent allergic rhinitis [1]. - The product has been assigned a medical insurance payment standard of 1.78 yuan per tablet, with the agreement effective from January 1, 2026, to December 31, 2027 [1]. - The company holds complete intellectual property rights for Qifang Bitong Pian, which received its drug registration certificate from the National Medical Products Administration in January 2025 [1]. Group 2: Impact on Company Operations - In addition to Qifang Bitong Pian, the company has 11 other proprietary products included in the National Medical Insurance Directory for 2025, which may positively influence the company's market promotion and sales growth [2]. - The inclusion of these 12 proprietary traditional Chinese medicine products in the insurance directory is expected to have a favorable long-term impact on the company's operational development, although the short-term effects on financial performance are currently uncertain [2].

Core Viewpoint - Yiling Pharmaceutical's subsidiary, Beijing Yiling, has successfully negotiated for its exclusive product, Qifang Nasal Tablets, to be included in the National Medical Insurance Directory (2025 edition) for the first time [1] Group 1: Company Developments - Yiling Pharmaceutical has a total of 12 exclusive products included in the National Medical Insurance Directory (2025 edition), which includes Qifang Nasal Tablets and other products such as Tongxinluo Tablets (Capsules), Ginseng and Pine Nut Heart Nourishing Capsules, and Lianhua Qingwen Tablets (Capsules, Granules) [1] - The inclusion of these products in the medical insurance directory is expected to enhance their market accessibility and potentially increase sales [1] Group 2: Industry Impact - The addition of Yiling Pharmaceutical's products to the National Medical Insurance Directory reflects a broader trend in the industry towards integrating traditional Chinese medicine into the national healthcare system [1] - This move may encourage other companies in the industry to seek similar negotiations for their products, potentially leading to increased competition and innovation within the sector [1]

Core Insights - The article highlights the successful global registration and commercialization of 17 innovative traditional Chinese medicine (TCM) products by Yiling Pharmaceutical, marking a significant step in the internationalization of TCM [1][5][6] - Yiling Pharmaceutical has established a clear pathway for TCM's global integration, moving from physical expansion to cultural integration and value leadership [1][5] Group 1: Global Expansion of TCM - Yiling Pharmaceutical has successfully registered its innovative TCM products in over 50 countries and regions, demonstrating the global reach of Chinese medicine [1][5] - The company emphasizes the importance of theoretical foundations in TCM's internationalization, having developed a comprehensive theory system around "Luo disease" over 33 years [5][6] - The establishment of various international academic exchange platforms has facilitated the global dissemination and research of Luo disease theory [6][9] Group 2: Cultural Integration and Market Strategies - Yiling Pharmaceutical adopts a differentiated market strategy, tailoring its approach to meet the specific medical needs and cultural contexts of different regions [7][8] - In developed countries, the focus is on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, the company integrates its products into local healthcare systems [7][8] - The successful inclusion of Tongxinluo capsules in Vietnam's healthcare system exemplifies the company's effective local integration strategy [7] Group 3: Evidence-Based Medicine and Research - Yiling Pharmaceutical leads in evidence-based research, establishing a robust research framework that supports the clinical efficacy of its TCM products [9][10] - The company has conducted over 40 high-quality evidence-based studies on its innovative TCM products, with significant findings published in prestigious international medical journals [10][12] - This research not only validates the safety and efficacy of TCM but also presents its benefits in modern scientific language, enhancing its global acceptance [10][12] Group 4: Future Outlook and Challenges - Despite the progress, Yiling Pharmaceutical acknowledges ongoing challenges in cultural recognition and regulatory policies, particularly in non-Belt and Road countries [12] - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers and further the global impact of TCM [12]

Core Insights - The 21st International Lymphatic Disease Conference overseas forum was held in Hanoi, Vietnam, focusing on the clinical application and research progress of lymphatic disease theory, showcasing achievements in research and discipline construction to promote the high-quality development of traditional Chinese medicine globally [1][2] Group 1: Conference Highlights - The forum was co-hosted by the World Federation of Chinese Medicine Societies Lymphatic Disease Professional Committee and the Vietnam Southern Medicine Association, featuring experts from Vietnam, China, Thailand, Romania, and other regions [1] - 17 lymphatic drugs developed under the guidance of lymphatic disease theory have been registered and launched in over 50 countries and regions [2] - The conference emphasized the significance of traditional medicine exchanges between China and Vietnam, especially in the context of the 75th anniversary of diplomatic relations [2] Group 2: Research and Development - Professor Wu Yiling and his research team have spent over 40 years developing a systematic theoretical framework for lymphatic disease, which is considered a milestone in the history of traditional Chinese medicine [2] - Multiple international academic exchange platforms have been established, including the Chinese Medicine Society Lymphatic Disease Branch and the European Lymphatic Disease Society, promoting the global dissemination of lymphatic disease theory [3] - Breakthroughs in the prevention and treatment of cardiovascular diseases, strokes, respiratory diseases, endocrine system diseases, and chronic diseases have been reported, showcasing the potential of lymphatic disease theory in modern medicine [3] Group 3: Educational Initiatives - Three major theoretical frameworks related to lymphatic disease have been published, and the English version of the textbook "Lymphatic Disease Studies" is being taught in over 40 overseas educational institutions [4] - Research results on various innovative traditional Chinese medicines have been published in prestigious international medical journals, validating their efficacy and safety [4] - The inclusion of "Traditional Chinese Medicine Lymphatic Disease Diagnosis and Treatment Methods" in the national intangible cultural heritage highlights the recognition and importance of this field [5]

Core Viewpoint - The article emphasizes the importance of traditional Chinese medicine (TCM) internationalization through theoretical foundations, scientific innovation, and cultural integration, highlighting Yiling Pharmaceutical's efforts in promoting TCM globally [5][7][9]. Group 1: Theoretical Foundation and Academic Development - Yiling Pharmaceutical has established a comprehensive theoretical framework for "Luo Disease" over 33 years, which is considered a significant milestone in TCM development [5]. - The company has published several authoritative texts on Luo Disease, including "Luo Disease Studies" and "Meridian Theory," which are used in international educational institutions to train TCM professionals [5][6]. - Yiling has created multiple academic exchange platforms globally, including various international associations and conferences, to promote the study and dissemination of Luo Disease theory [6]. Group 2: Market Strategies and Cultural Integration - The company adopts a differentiated market strategy, "one country, one policy," to align with the medical needs and cultural contexts of different regions [7]. - In developed countries, Yiling focuses on high-level clinical research to gain trust from the academic and regulatory communities, while in emerging markets, it integrates products into local healthcare systems [7]. - The successful inclusion of Tongxinluo capsules in Vietnam's medical insurance directory exemplifies the company's effective local integration [7]. Group 3: Evidence-Based Research and International Recognition - Yiling Pharmaceutical has pioneered evidence-based research in TCM since 1995, establishing a robust research system and innovation platform [9][10]. - The company has conducted over 40 high-quality evidence-based studies on its 17 innovative TCM products, with significant findings published in prestigious international medical journals [9][10]. - These studies validate the efficacy and safety of TCM, presenting its wisdom in modern scientific language, thus facilitating international recognition [10]. Group 4: Future Outlook and Challenges - Yiling Pharmaceutical acknowledges the challenges of cultural recognition and regulatory policies in non-Belt and Road countries for TCM's international expansion [12]. - The company believes that collaboration among government, industry, academia, and research institutions is essential to overcome these barriers [12]. - There is confidence that by balancing tradition and innovation, TCM can contribute significantly to global health governance [12].

Core Insights - Yiling Pharmaceutical has evolved from a local Hebei company to an international pharmaceutical group, establishing over 130 specialized committees for "Luo Disease" both domestically and internationally [3][5] - The company emphasizes technological innovation as its foundation, having developed 17 patented traditional Chinese medicines that address significant clinical gaps and are included in over 200 clinical guidelines [3][5] Group 1: Innovation and R&D - The "Luo Disease Theory" is a unique component of traditional Chinese medicine and serves as the core of Yiling's R&D system, leading to a five-in-one operational model that integrates theory, clinical practice, research, industry, and education [5][6] - In the first three quarters of the year, Yiling achieved a net profit of 1 billion yuan, representing an 80.33% year-on-year increase, with R&D expenses amounting to 544 million yuan, accounting for 9.27% of revenue [6][7] - The company's cardiovascular products have increased their market share from 13.64% in 2015 to 18.13% in 2024, demonstrating the direct correlation between R&D and market competitiveness [6][7] Group 2: International Expansion - Yiling is actively promoting traditional Chinese medicine globally, establishing over 130 specialized committees and conducting international academic exchanges to enhance its academic brand's influence [7][8] - The company’s products have been featured in top international medical journals, showcasing their efficacy in reducing risks associated with cardiovascular events [6][7] Group 3: Business Model and Future Growth - Yiling's business model consists of three main pillars: patented traditional Chinese medicine, chemical/biological drugs, and health industry, aiming for a synergistic development of the pharmaceutical health ecosystem [8] - The company is well-positioned for rapid growth in product lines related to aging, with a focus on cardiovascular health, anti-aging, and endocrine products over the next 3 to 5 years [8]

Group 1 - The core viewpoint of the article highlights the strategic developments and growth trajectories of various companies in Hebei, including their market performance and innovative initiatives [11][19][20]. - Hebei's listed companies have implemented market value management plans, with 74 companies executing annual and mid-term dividends totaling over 28 billion yuan [11]. - Yiling Pharmaceutical has increased its market share in the cardiovascular oral traditional Chinese medicine market from 13.64% in 2015 to 18.13% in 2024, serving as a stable growth driver for the company [11][28]. Group 2 - Wireless Media is expanding its business from traditional IPTV services to smart home and enterprise digitalization, aiming to redefine the value of large screens through technology [12][13]. - The company has a user base of nearly 15 million IPTV subscribers, and it is actively developing a smart media cloud platform to create a new ecosystem combining AI and new media [13][15]. - Financial support for local enterprises has been significant, with Financial Securities issuing 8 rounds of science and technology bonds totaling 8.2 billion yuan to support R&D investments [20][23]. Group 3 - Colin Electric aims to become a world-class comprehensive energy service provider by integrating smart grids, renewable energy, and comprehensive energy services [32][34]. - The company has seen significant growth in its renewable energy sector, focusing on photovoltaic and energy storage solutions, and is transitioning from equipment supplier to integrated solution provider [33][36]. - In the third quarter, Colin Electric reported a revenue of 3.216 billion yuan, a year-on-year increase of 23.63%, and a net profit of 217 million yuan, marking a 45.9% increase [36]. Group 4 - Yiling Pharmaceutical has established a comprehensive R&D system guided by the theory of "Luo Disease," leading to the successful development of 17 patented traditional Chinese medicines [26][28]. - The company emphasizes the importance of R&D as a core growth driver, with R&D expenses accounting for 9.27% of revenue, positioning it among the leaders in the traditional Chinese medicine industry [28][29]. - Yiling's products have gained international recognition, with significant studies published in top medical journals demonstrating their efficacy in treating cardiovascular conditions [29][30].

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) has demonstrated strong performance in Q3 2025, with revenue of 1.827 billion yuan, a year-on-year increase of 3.78%, and a significant growth in net profit, indicating robust business fundamentals and potential for future growth [3][4]. Business Foundation - The company has a solid foundation in traditional Chinese medicine, with 17 patented products, 11 of which are included in the national medical insurance directory, ensuring stable growth [4][5]. - Key products such as Tongxinluo Capsule and Qiyuqiangxin Capsule have maintained top positions in the cardiovascular market, supported by clinical guidelines [5]. Growth Potential - The biopharmaceutical segment is advancing with a strategy that includes both generic and innovative drug development, leading to a second growth phase [6][7]. - The health segment targets specific consumer needs, tapping into a trillion-level health consumption market, which provides new growth opportunities [6][7]. R&D Investment - Yiling Pharmaceutical invested 544 million yuan in R&D in the first three quarters of 2025, leading the domestic traditional Chinese medicine sector, with cumulative R&D investment exceeding 5 billion yuan from 2019 to 2024 [6][7]. - The company has established a robust pipeline with multiple products in various stages of development, ensuring sustainable growth [7][8]. International Expansion - The company has expanded its international presence, with products like Tongxinluo Capsule and Qiyuqiangxin Capsule entering over 50 countries, enhancing its global market reach [10][11]. Shareholder Returns - The company has shown commitment to shareholder returns, with earnings per share reaching 0.5988 yuan, a year-on-year increase of 80.31%, and a dividend payout of 5.01 billion yuan, representing 77% of the profit [11].